Nordion Launches a New and Improved TheraSphere® Website to Meet the Needs of Liver Cancer Physicians, Patients and Caregivers Worldwide
TheraSphere.com provides unique resources and targeted information about this innovative radioembolization therapy
OTTAWA, Ontario--(BUSINESS WIRE)-- Nordion Inc. (NDZ) (TSX: NDN) (NYSE: NDZ), a leading provider of products and services for the prevention, diagnosis and treatment of disease, announced today that it has launched a new and improved, intuitive, feature-rich TheraSphere® website, providing liver cancer patients and physicians with customized TheraSphere® resources that include medical and clinical information, convenient online ordering, and innovative digital resources.
The new website highlights the resources and programs that make TheraSphere® a truly unique treatment offering, said Steve West, Nordion CEO and Chief Operating Officer, Targeted Therapies. With physicians and patients increasingly seeking digital delivery of treatment information and resources, the new TheraSphere.com website is the global hub that connects our users to a complete suite of training and support, whether theyre administrating their first TheraSphere® dose or their 100th.
Specifically for physicians, the site offers convenient online access to a suite of unique TheraSphere® resources, including:
- TheraSphere® Preceptor Program: Connects physicians with experienced interventional radiologists that provide medical and technical advice to treatment users.
- TheraSphere® Resource Center iPad App: A comprehensive educational tool designed for healthcare professionals, placing valuable product information at their fingertips.
- Online Ordering for Standard and Custom Doses: TheraSphere® users can order product online or by email, phone or fax. This includes custom doses, which are designed to provide greater treatment flexibility for physicians, save administration time and reduce product waste.
- Expanded clinical trial information: Up-to-date information on TheraSphere® Phase III clinical trials, which include YES-P (liver cancer patients with portal vein thrombosis) STOP-HCC (patients with hepatocellular carcinoma) and EPOCH (patients with colorectal cancer whose disease has metastasized to the liver).
In addition to the TheraSphere® animation video and comprehensive Patient Information Guide, liver cancer patients and caregivers around the world can now find product information in their language, on dedicated pages offering quick access to treatment centers and resources specific to their location.
The new TheraSphere.com website is optimized for mobile devices and all modern browsers, to meet the needs of users on the go, on their platform of choice.
To learn more, visit the Nordion booth at the following interventional oncology industry events:
SSO Society of Surgical Oncology Cancer Symposium
National Harbor, MD
Gaylord National Hotel
March 6 - 9, 2013
SIR Society of Interventional Radiology
New Orleans, LA
Ernest N. Morial Convention Center
April 13 - 18, 2013
TheraSphere® is a liver cancer therapy that consists of millions of small glass beads (20 to 30 micrometers in diameter) containing radioactive Y-90. The product is injected by physicians into the artery of the patients liver through a catheter, which allows the treatment to be delivered directly to the tumour via blood flow.
In the US, TheraSphere® is used to treat patients with hepatocellular carcinoma (HCC) who can have appropriately positioned hepatic arterial catheters, and can be used as a bridge to surgery or transplantation in these patients. It is also indicated for the treatment of HCC patients with partial or branch portal vein thrombosis or occlusion when clinical evaluation warrants the treatment. TheraSphere® is approved by the U.S. Food and Drug Administration (FDA) under a Humanitarian Device Exemption (HDE). HDE approvals are based on demonstrated safety and probable clinical benefit. However, effectiveness of the indication for use has not been established.
TheraSphere® is used in the European Union and in Canada for the treatment of hepatic neoplasia in patients who have appropriately positioned arterial catheters.
Common side effects include mild to moderate fatigue, pain and nausea for about a week. Physicians describe these symptoms as similar to those of the flu. Some patients experience some loss of appetite and temporary changes in several blood tests. For details on rare or more severe side effects, please refer to the TheraSphere® Package Insert/Instructions for Use at www.nordion.com/therasphere.
About Nordion Inc.
Nordion Inc. (TSX: NDN) (NYSE: NDZ) is a global health science company that provides market-leading products used for the prevention, diagnosis and treatment of disease. We are a leading provider of targeted therapies, sterilization technologies and medical isotopes that benefit the lives of millions of people in more than 60 countries around the world. Our products are used daily by pharmaceutical and biotechnology companies, medical-device manufacturers, hospitals, clinics and research laboratories. Nordion has approximately 500 highly skilled employees worldwide. Find out more at www.nordion.com and follow us at http://twitter.com/NordionInc.
Shelley Maclean, 613-592-3400 x. 2414
Ana Raman, 613-595-4580
Source: Nordion Inc.Copyright Business Wire 2013